NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

Marcus Ruscetti(Memorial Sloan Kettering Cancer Center), Josef Leibold(Memorial Sloan Kettering Cancer Center), Matthew J. Bott(Memorial Sloan Kettering Cancer Center), Myles Fennell(Memorial Sloan Kettering Cancer Center), Amanda Kulick(Memorial Sloan Kettering Cancer Center), Nelson R. Salgado(Memorial Sloan Kettering Cancer Center), Chi-Chao Chen(Memorial Sloan Kettering Cancer Center), Yu-Jui Ho(Memorial Sloan Kettering Cancer Center), Francisco J. Sánchez‐Rivera(Memorial Sloan Kettering Cancer Center), Judith Feucht(Memorial Sloan Kettering Cancer Center), Timour Baslan(Memorial Sloan Kettering Cancer Center), Sha Tian(Memorial Sloan Kettering Cancer Center), Hsuan-An Chen(Memorial Sloan Kettering Cancer Center), Paul B. Romesser(Memorial Sloan Kettering Cancer Center), John T. Poirier(Memorial Sloan Kettering Cancer Center), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Elisa de Stanchina(Memorial Sloan Kettering Cancer Center), Eusebio Manchado(Memorial Sloan Kettering Cancer Center), Charles J. Sherr(St. Jude Children's Research Hospital), Scott W. Lowe(Memorial Sloan Kettering Cancer Center)
Science
December 20, 2018
Cited by 433Open Access
Full Text

Abstract

Molecularly targeted therapies aim to obstruct cell autonomous programs required for tumor growth. We show that mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 4/6 inhibitors act in combination to suppress the proliferation of KRAS-mutant lung cancer cells while simultaneously provoking a natural killer (NK) cell surveillance program leading to tumor cell death. The drug combination, but neither agent alone, promotes retinoblastoma (RB) protein-mediated cellular senescence and activation of the immunomodulatory senescence-associated secretory phenotype (SASP). SASP components tumor necrosis factor-α and intercellular adhesion molecule-1 are required for NK cell surveillance of drug-treated tumor cells, which contributes to tumor regressions and prolonged survival in a KRAS-mutant lung cancer mouse model. Therefore, molecularly targeted agents capable of inducing senescence can produce tumor control through non-cell autonomous mechanisms involving NK cell surveillance.


Related Papers